AgeneBio Obtains National Institute on Aging Grant for Phase 3 Trial of Its Alzheimer’s Therapy AGB101

AgeneBio Obtains National Institute on Aging Grant for Phase 3 Trial of Its Alzheimer’s Therapy AGB101
AgeneBio has obtained a National Institute on Aging grant to conduct a Phase 3 clinical trial of AGB101 (levetiracetam), a compound intended to prevent people with mild memory impairment from developing Alzheimer’s disease. The agency, part of the National Institutes of Health (NIH), has been backing the potential therapy's development for some time. AgeneBio did not announce the size of the latest grant. "With the award of this additional funding from the NIH, we will immediately initiate the Phase 3 trial start-up with an initial cohort of clinical sites and expect to enroll the first patient during the first quarter of 2018," Richard Mohs, AgeneBio's Vice President of Clinical Development, said in a press release. The trial, called HOPE4MCI, will continue examining AGB101's ability to slow or reverse cognitive decline. A Phase 2 clinical trial (NCT01044758) showed that the compound improved memory performance. Researchers believe the potential therapy will also be successful in the Phase 3 study. "We expect the HOPE4MCI trial to demonstrate efficacy in preserving cognition and memory in MCI [mild cognitive impairment] due to AD [Alzheimer’s disease] patients while delaying progression to the clinical stage of Alzheimer's dementia," Mohs said. AGB101 is an updated version of an epilepsy drug that has been on the market for two decades. Its extended-release formulation is one-twelfth the dose used to
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *